Neuroendocrine Prostate Cancer (NEPC)
4 clinical trials · Condition
◉ Watch Neuroendocrine Prostate Cancer (NEPC)
| Record | Firm | Date |
|---|---|---|
| Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy (NCT07639086) | Virginia Commonwealth University | 2026-08-31 |
| A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) (NCT07488923) | Moonlight Bio, Inc | 2026-06-01 |
| Memantine Hydrochloride in Prostate Cancer Patients (NCT07164794) | Bin Xu | 2025-11-01 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686) | Phanes Therapeutics | 2023-09-05 |
Track Neuroendocrine Prostate Cancer (NEPC) automatically
Every clearance here is in the API, with alerts when new ones post.